Investor Relations

Press Releases


NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)

Includes Data from More than Twenty-Five Studies, Including Six Using GeoMx Digital Spatial Profiler

SEATTLE, Nov. 07, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in understanding of immune response and cancer immunotherapy using the nCounter® and GeoMx™ platforms that will be presented at the 33nd Annual Meeting of the Society of Immunotherapy for Cancer (SITC).

“We are thrilled to see a number of high-profile abstracts that include data from our GeoMx Digital Spatial Profiler at the 2018 SITC conference,” said Brad Gray, president and chief executive officer of NanoString. “The ability to quantify high-plex protein and RNA simultaneously can be a powerful tool for identifying and validating biomarkers, especially for applications in immuno-oncology.”

More than 25 abstracts using NanoString’s nCounter platform will be presented at the SITC Annual Meeting, being held at the Walter E. Washington Convention Center in Washington, D.C., Nov. 7-11, 2018. The research being presented spans a wide breadth of applications, including biomarker development, the study of immune responsiveness and resistance, and digital pathology.

Six studies included the use of NanoString’s GeoMx Digital Spatial Profiler (DSP) platform in immuno-oncology research.  These abstracts include numbers 031, P113, P131, P389, P428 and P429 that are included in the table below. DSP allows for digital quantification of protein and gene expression from discrete regions of FFPE tissue in an automated and multiplex format.  DSP is expected to be commercially available with the launch of a new instrument planned for mid-2019, and is currently accessible through the company’s Technology Access Program (TAP). NanoString is currently accepting applications for the TAP for its DSP technology at TAP@Nanostring.com.  

Each year, SITC recognizes publications that demonstrated excellence in scientific research with its Journal for ImmunoTherapy of Cancer (JITC) best paper awards.  The 2018 JITC “Best Basic Science Paper” was awarded for “Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA),” to a team led by NanoString researchers that included, Patrick Danaher, Ph.D., Sarah Warren, Ph.D., Rongze Lu, Ph.D., Josue Samayoa, Ph.D., Amy Sullivan, B.S., Irena Pekker, Ph.D., Brett Wallden, M.S., Francesco M. Marincola, M.D., and Alessandra Cesano, M.D., Ph.D.

NanoString will host a Key Opinion Leader Dinner for Digital Spatial Profiling on the evening of Thursday, Nov. 8th. The dinner features presentations by leading academic and biopharma researchers on the use of nCounter gene expression and GeoMx Digital Spatial Profiling technologies to discover biomarkers for treating bladder cancer and melanoma.

At the 2018 SITC Annual Meeting, NanoString will showcase its nCounter platform, IO360 and Data Analysis and Digital Spatial Profiling at booth #600.

Abstract # Title Presenting Author
O31


Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma

David Page, MD
Providence Portland Cancer Center, Portland, OR,
USA
O45

Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444 Lawrence Fong, MD
University of California, San Francisco, CA, USA
P25

Consistent pharmacodynamics and immunological responses to the TLR9 agonist, SD-101, following intratumoral injection in multiple cancer types Albert Candia, PhD
Dynavax Technologies, Berkeley, CA, USA
P35

Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928 Daniel DiRenzo, PhD
Arcus Biosciences, Hayward, CA, USA
P43


The presence of exhausted CD8+ T cells identifies a subset of immunogenic ER+ breast cancer patient tumors


Colt Egelston, PhD
Beckman Research Institute, City of Hope, Duarte,
CA, USA
P53

X4P-001, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and tumor inflammatory status in the microenvironment of melanoma Robert Andtbacka, MD
Huntsman Cancer Institute, Salt Lake City, UT, USA
P54

Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444 Andrew Hotson, PhD
Corvus Pharmaceuticals, Burlingame, CA, USA
P67

Innovative combinatorial approach to characterize the immune landscape and analyze the tumor response after anti-PD-1 blockade in a 3D ex-vivo tumoroid system of non-small cell lung cancer Melba Marie Page, PhD
Nilogen Oncosystems, Tampa, FL, USA
P87


Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial

Luc R. Desnoyers, PhD
CytomX Therapeutics, Inc., South San Francisco, CA,
USA
P113

Digital spatial profiling of bone-marrow infiltrating immune cells in acute myeloid leukemia

Sergio Rutella, MD, PhD
Nottingham Trent University, Nottingham, UK
P131


High-plex predictive marker discovery for melanoma immunotherapy treated patients using NanoString® Digital Spatial Profiling

David Rimm, MD, PhD
Yale University School of Medicine, New Haven, CT,
USA
P136

Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumab Breelyn Wilky, MD
University of Miami - SCCC, Miami, FL, USA
P139

"Pharmacodynamic effects of CA170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of T-cell Funda Meric-Bernstam, MD
MD Anderson Cancer Center, Houston, USA
P327

Higher dose single-agent intratumoral G100 (a TLR4 agonist) results in increased biomarker activity and improved clinical outcomes in patients with follicular lymphoma Ahmad Halwani, MD
Huntsman Cancer Institute, Salt Lake City, UT, USA
P349

Spatial distribution analysis reveals increased PD1 expression on cytotoxic T cells leading to tumor regression upon combined MEK and HDAC inhibition in spontaneous PDAC mouse model Phyllis Cheung, PhD
University Hospital Essen, DKFZ, Essen, Germany
P354

Co-clinical trials of MEK inhibitor, anti PD-L1 and anti CTLA-4 combination treatment in Non-Small Cell Lung Cancer

Pierre-Olivier Gaudreau
MD Anderson Cancer Center, Houston, USA
P360

Enhanced anti-tumor efficacy of mesothelin-targeted immunotoxin LMB-100 combined with anti-PD-1 antibody

Qun Jiang, PhD
National Institutes of Health, Bethesda, MD, USA
P389

Digital spatial profiling on uveal melanoma tissue treated with combined radiofrequency ablation and ipilimumab

Trieu My Van, PhD
NKI/Nanostring, Amsterdam, Netherlands
P428

Spatially-resolved, high-plex digital profiling enables characterization of complex immune biology of the colorectal cancer microenvironment Sarah Church, PhD
NanoString Technologies, Seattle, WA, USA
P429


Integrative spatially-resolved, high-plex digital profiling enables characterization of complex immune biology in the tumor microenvironment of mesothelioma

Carmen Ballesteros Merino, PhD, Providence Portland Cancer Center, Portland, OR,
USA
P450

The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory activity and enhances immune checkpoint blockade in syngeneic mouse models Luis Carvajal, PhD
Aileron Therapeutics, Inc., Cambridge, MA, USA
P460

Chemotherapy induced immunogenic cell death and response to STING agonist in high-grade serous ovarian cancer

Sarah Nersesian, MSc
Queen's University, Kingston, ON, Canada
P468

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod Mariya Rozenblit, MD
Yale University, Connecticut, CT, USA
P564

Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated enterocolitis

Daniel Johnson, MD
MD Anderson Cancer Center, Houston, TX, USA
P597

Reovirus infection of prostate cancer induces upregulation of the negative regulators PD-L1 and BTLA

Nicola Annels, PhD
The University of Surrey, Guildford, UK
P614

Nano-Pulse Stimulation™ of murine melanoma and mammary carcinoma is a physical modality that eliminates the treated tumor by regulated cell death and induces innate and adaptive immune responses Amanda McDaniel, BA
Pulse Biosciences, Burlingame, CA, USA
P650

Selective CD47 immune checkpoint targeting on tumor cells modulates the tumor microenvironment to enhance macrophage tumoricidal function Vanessa Buatois, PhD
Novimmune SA, Geneva, Switzerland

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit www.nanostring.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the capabilities of the company's current and future products and the timing of future product launches. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; the impact of competition; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

NanoString, NanoString Technologies, the NanoString logo, GeoMx DSP, 3D Biology, 3D Flow, nCounter, PanCancer IO360 and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contact:

Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

 

nano.jpg

Source: NanoString Technologies, Inc.